Cardiovascular therapies and neuromodulation devices by CVRx
CVRx brings Michael Dale onto board to leverage leadership in medical devices
CVRx has appointed Michael Dale as a new member of its Board of Directors. Dale brings decades of leadership experience in the medical device sector and is known for a strong track record in ...
CVRx celebrates 50th Barostim implant milestone at Wellstar Kennestone
CVRx has congratulated Dr. Ryan Burke, Dr. Brian Howard, Dr. Latif Bikak, and the team at Wellstar Kennestone for reaching the milestone of their 50th Barostim implant. This accomplishment ...
CVRx targets clinical integration of Barostim with hands on symposium at AAHFN2026
CVRx has announced its participation in AAHFN2026, where the company will host an interactive dinner symposium focused on the role of Advanced Practice Providers in patient selection and the ...
CVRx publishes BENEFIT-HF trial design in peer-reviewed journal
CVRx has announced the publication of the BENEFIT-HF trial design paper in the Journal of Cardiac Failure. The article presents the methodology for a prospective, randomized, controlled, ...
Clinical research teams accelerate progress in treatment options, CVRx asserts
CVRx recognizes the important role of researchers and healthcare professionals who advance the science underpinning better patient care. The company emphasized that clinical trials are essential ...
CVRx marks 25th Barostim implant milestone at UNC Medical Center Chapel Hill
CVRx has announced the successful completion of the 25th Barostim implant at UNC Medical Center in Chapel Hill. The accomplishment recognizes the contributions of Dr. William Tripp Mostertz, ...
Humana expands Barostim therapy access via Medicare Advantage, CVRx secures national deal
CVRx has announced that Humana will issue a Medicare Advantage coverage policy for Barostim therapy, with the policy set to become effective on May 1, 2026. Humana is one of the largest national ...
CVRx revenue rises 20 percent in first quarter as U.S. operations expand
CVRx reported a 20 percent increase in total revenue for the first quarter, signaling robust growth compared to the same period last year. The company also recorded a 22 percent surge in U.S. ...
CVRx launches landmark BENEFIT-HF trial for cardiac device research
CVRx has announced the first patient enrollment in the BENEFIT-HF trial at North Central Heart, a division of the Avera Heart Hospital in Sioux Falls, South Dakota. This groundbreaking trial, ...
CVRx reports Barostim therapy boosts quality of life for heart failure patients
CVRx announced that Dr. Savitri Fedson has shared a real-world account highlighting the impact of Barostim therapy on heart failure patients. According to Dr. Fedson, patients using Barostim have ...
Methodist University Hospital completes first Barostim implant with CVRx collaboration
CVRx and Methodist University Hospital have announced the successful completion of the hospital's first Barostim implant, a novel device therapy aimed at improving symptoms for patients with heart ...
CVRx promotes Barostim therapy as new option for heart failure patients at ISHLT2026
CVRx is spotlighting its Barostim device therapy at ISHLT2026, emphasizing its potential to improve exercise capacity and quality of life for individuals with heart failure. The company ...
Lawnwood Medical Center achieves milestone with 15th Barostim therapy, CVRx confirms
CVRx announced that Dr. Philip Seibel and the team at Lawnwood Medical Center have successfully completed their 15th Barostim implant. This milestone reflects sustained efforts to provide ...
CVRx unveils Barostim session on neurohormonal targeting at ISHLT2026
CVRx is set to present a session titled Barostim: Flipping the Parasympathetic Switch at the upcoming ISHLT2026 conference. The session will focus on how Barostim technology complements ...
CVRx expects robust 20 percent revenue growth in preliminary Q1 results
CVRx has announced its preliminary first-quarter 2026 financial results, projecting revenue between 14.7 million and 14.8 million dollars and indicating approximately 20 percent growth compared to ...
CVRx touts Barostim therapy as improving exercise capacity in heart failure beyond GDMT alone
CVRx is promoting its Barostim device at #ACC26, emphasizing the treatment's ability to enhance exercise capacity and quality of life for heart failure patients where guideline-directed medical ...
First Barostim procedure at Ascension Alexian Brothers backed by CVRx
CVRx has supported the inaugural Barostim implant performed by Dr. Georges Haidar, Dr. Ashish Haryani, Dr. Baqir Lakhani, and the clinical team at Ascension Alexian Brothers. This milestone ...
CVRx enables first Barostim implant at Baptist Medical Center expanding heart failure treatment options
CVRx supported Dr. Meenakshi Bhalla, Dr. Thomas Pollard, and the medical team at Baptist Medical Center in performing their first Barostim implant. This milestone brings a new device-based ...
Barostim device transforms life after severe heart failure, CVRx asserts
CVRx reports that the Barostim device enabled a heart failure patient named David to regain significant quality of life after a period of severe physical limitation. Previously, David ...
CVRx to present late-breaking THT2026 data in clinical webinar
CVRx will host a webinar on Thursday, March 12 to review late-breaking data from THT2026. The event will feature Chief Medical Officer Dr. Philip Adamson moderating a roundtable with Dr. Farooq ...
CVRx opens THT2026 with new scientific data on Barostim outcomes
CVRx launches THT2026 today, featuring a comprehensive program of scientific presentations focused on Barostim. Attendees will gain insight from late-breaking clinical data, oral sessions, and ...
